Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.59 |
| ▸ | ADH1B | P00325 | 1/20 | 0.55 |
| ▸ | ADH1C | P00326 | 1/20 | 0.55 |
| ▸ | ADH1A | P07327 | 1/20 | 0.55 |
| ▸ | ADH7 | P40394 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.43 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1983770 | 0.94 | LOXL2 (0.53) | LOXL2ADH1BADH1CADH1AADH7 | |
| SCHEMBL8763196 | 0.82 | ADH1B (0.76) | ADH1BADH1CADH1AADH7ALDH1A1 | |
| SCHEMBL6562365 | 0.81 | CA12 (0.51) | LOXL2CYP19A1CYP2A6CA12CA1 | |
| SCHEMBL23879203 | 0.81 | LOXL2 (0.71) | LOXL2CYP19A1CYP2A6CA12CA1 | |
| SCHEMBL25629446 | 0.80 | ADH1B (0.55) | LOXL2ADH1BADH1CADH1AADH7 | |
| SCHEMBL24185722 | 0.80 | LOXL2 (0.59) | LOXL2CYP19A1CYP2A6CA12CA1 | |
| SCHEMBL12500340 | 0.78 | TSHR (0.46) | LOXL2CYP19A1CYP2A6CA12CA1 | |
| SCHEMBL12500205 | 0.78 | ADH1B (0.53) | ADH1BADH1CADH1AADH7CYP19A1 | |
| SCHEMBL4633427 | 0.77 | ADH1B (0.52) | LOXL2ADH1BADH1CADH1AADH7 | |
| SCHEMBL29912750 | 0.77 | LOXL2 (0.65) | LOXL2CYP19A1CYP2A6CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130302-A1 | Antiviral Pyrazolopyridinone Compounds | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC | 2021-05-06 | — | — | US | claimed |
| EP-2661436-B1 | NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2016-04-13 | — | — | EP | claimed |
| US-9233964-B2 | Sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use therof | LEO PHARMA A/S (DK) | 2016-01-12 | — | — | US | claimed |
| US-20130345194-A1 | SUBSTITUTED CYCLOPENTYL-AZINES AS CASR-ACTIVE COMPOUNDS | LEO PHARMA A/S (DK) | 2013-12-26 | — | — | US | claimed |
| EP-2661436-A1 | NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | Leo Pharma A/S (DK) | 2013-11-13 | — | — | EP | claimed |
| WO-2012093169-A1 | NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2012-07-12 | — | — | WO | claimed |
| US-20250353820-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | NOVARTIS AG (CH) | 2025-11-20 | — | — | US | disclosed |
| US-12338220-B2 | Antiviral pyrazolopiridinone compounds | GILEAD SCIENCES, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20230365511-A1 | Antiviral Pyrazolopiridinone Compounds | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| EP-3781553-B1 | HETEROARYL-TRIAZOLE AND HETEROARYL-TETRAZOLE COMPOUNDS AS PESTICIDES | BAYER AG (DE) | 2023-08-23 | — | — | EP | disclosed |
| US-11667613-B2 | Antiviral pyrazolopyridinone compounds | NOVARTIS AG (CH) | 2023-06-06 | — | — | US | disclosed |
| EP-4034537-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | Novartis AG (CH) | 2022-08-03 | — | — | EP | disclosed |
| CN-114667285-A | Antiviral pyrazolopyridinone compounds | 诺华股份有限公司 | 2022-06-24 | — | — | CN | disclosed |
| EP-0594540-B1 | Antiretroviral acyl compounds | CIBA GEIGY AG (CH) | 1998-04-01 | — | — | EP | disclosed |
| WO-1998004542-A1 | CHROMAN DERIVATIVES | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1998-02-05 | — | — | WO | disclosed |
| US-5670497-A | RETROVIRAL PROTEASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1997-09-23 | — | — | US | disclosed |
| WO-1996039142-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PROTEINASE INHIBITOR AND A MONOGLYCERIDE | F. HOFFMANN-LA ROCHE AG (CH) | 1996-12-12 | — | — | WO | disclosed |
| EP-0708760-A1 | CYCLIC HYDRAZINE COMPOUNDS | Novartis AG (CH) | 1996-05-01 | — | — | EP | disclosed |
| WO-1995002582-A1 | CYCLIC HYDRAZINE COMPOUNDS | CIBA-GEIGY AG (CH) | 1995-01-26 | — | — | WO | disclosed |
| EP-0594540-A1 | Antiretroviral acyl compounds | CIBA-GEIGY AG (CH) | 1994-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345194-A1 | SUBSTITUTED CYCLOPENTYL-AZINES AS CASR-ACTIVE COMPOUNDS | JAK1, CNKSR1, TSHR | LOXL2 1226/4885ADH1B 921/4885ADH1C 1123/4885 |
| US-20250353820-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | ZC3HAV1, TYMP, ZC3HAV1L | LOXL2 4761/4885ADH1B 2836/4885ADH1C 2698/4885 |
| US-11667613-B2 | Antiviral pyrazolopyridinone compounds | ZC3HAV1, TYMP, ZC3HAV1L | LOXL2 4761/4885ADH1B 2836/4885ADH1C 2698/4885 |
| US-20230365511-A1 | Antiviral Pyrazolopiridinone Compounds | ZC3HAV1, ZC3HAV1L, RPL35 | LOXL2 4676/4885ADH1B 2745/4885ADH1C 4024/4885 |
| US-12338220-B2 | Antiviral pyrazolopiridinone compounds | ZC3HAV1, ZC3HAV1L, RPL35 | LOXL2 4676/4885ADH1B 2745/4885ADH1C 4024/4885 |
| US-20210130302-A1 | Antiviral Pyrazolopyridinone Compounds | ZC3HAV1, TYMP, ZC3HAV1L | LOXL2 4761/4885ADH1B 2836/4885ADH1C 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.